Annotation Detail

Information
Associated Genes
PDGFRA
Associated Variants
PDGFRA p.Asp842_Ile843delinsValMet (p.D842_I843delinsVM), ENSG00000282278 p.Asp602_Ile603delinsValMet (p.D602_I603delinsVM) ( ENST00000257290.10 )
PDGFRA p.Asp842_Ile843delinsValMet (p.D842_I843delinsVM), ENSG00000282278 p.Asp602_Ile603delinsValMet (p.D602_I603delinsVM) ( ENST00000257290.10 )
Associated Disease
gastrointestinal stromal tumor
Source Database
CIViC Evidence
Description
In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/47
Gene URL
https://civic.genome.wustl.edu/links/genes/38
Variant URL
https://civic.genome.wustl.edu/links/variants/102
Rating
4
Evidence Type
Predictive
Disease
Gastrointestinal Stromal Tumor
Evidence Direction
Supports
Drug
Crenolanib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
22745105
Drugs
Drug NameSensitivitySupported
CrenolanibSensitivitytrue